The gut microbiome plays a crucial role in human health, and the loss of these microbes can lead to disease. BiomeBank, a biotechnology company, is working to restore the gut microbial ecology through donor-derived microbiome therapy, which has been approved for the treatment of C. difficile infection in Australia. The company’s Consortiome platform allows for the development of artificial human gut microbial communities that can be targeted towards specific diseases, such as ulcerative colitis. The therapy BB265 has shown promise in inducing remission for UC patients. BiomeBank’s innovative approach to microbiome therapy offers potential solutions for a variety of diseases.
Source link
BiomeBank’s Product Offerings Unlock the Potential of Microbiome Therapy
